Johnson & Johnson has clinched an FDA approval for Caplyta in depression, satisfying a major driver for its $14.6bn takeover of ICT this year.

Today, healthcare isn’t what’s driving Oura’s business — technically. The revenue Oura receives from contracts with health plans and providers is “de minimis” right now,

Eli Lilly has raised the stakes in the obesity market with positive midstage data for its amylin-targeting drug eloralintide.

AstraZeneca takes another step forwards towards its target of growing revenues to $80bn by 2030, as quarterly sales top $15bn for the first time.

Moderna posted $1 billion in third-quarter revenue, down 45% from the same period a year ago, as shrinking vaccine uptake and a continued inability to